BioStock article about Alzinova gets green light to continue phase Ib study

Date: 2022-09-07

The company announced that the Data Safety Monitoring Board (DSMB) completed an additional planned safety assessment of the ongoing ALZ-101 Phase 1b clinical study and recommended continuation of the study. 

BioStock has picked up the news and contacted Alzinova’s Development Project Director Stefan Pierrou to learn more. Link to the full article below.

BioStock Article (in Swedish)